Early growth response-2 signaling mediates immunomodulatory effects of human multipotential stromal cells

Stem Cells and Development

Volumn 23, Issue 2, 2014, Pages 155-166

  Barbeau, Dominique J ^a   La, Kiet Tran ^a   Kim, Duk Soo ^a   Kerpedjieva, Svetoslava S ^a   Shurin, Galina V ^a   Tamama, Kenichi ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EARLY GROWTH RESPONSE FACTOR 2; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE DIOXYGENASE 1; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; PROSTAGLANDIN E2; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; PROSTAGLANDIN SYNTHASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; EGR2 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; LIF PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ARTICLE; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN RELEASE; PROTEIN BINDING; BIOLOGICAL THERAPY; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 2; HUMANS; IMMUNOMODULATION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84891839549     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0194     Document Type: Article

References (54)

1. Blazar BR, WJ Murphy and M Abedi. (2012). Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12:443-458.
2. Ohashi PS. (2002). T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol 2: 427-438.
3. Buckley CD, DW Gilroy, CN Serhan, B Stockinger and PP Tak. (2013). The resolution of inflammation. Nat Rev Immunol 13:59-66.
4. Friedenstein AJ, JF Gorskaja and NN Kulagina. (1976). Fi-broblast precursors in normal and irradiated mouse hema-topoietic organs. Exp Hematol 4:267-274.
5. Oswald J, S Boxberger, B Jorgensen, S Feldmann, G Ehnin-ger, M Bornhauser and C Werner. (2004). Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22:377-384.
6. Owen M and AJ Friedenstein. (1988). Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp 136:42-60.
7. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
8. Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74.
9. Tamama K, VH Fan, LG Griffith, HC Blair and A Wells. (2006). Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells 24:686-695.
10. Tamama K, CK Sen and A Wells. (2008). Differentiation of bone marrow mesenchymal stem cells into the smooth muscle lineage by blocking ERK/MAPK signaling pathway. Stem Cells Dev 17:897-908.
11. Kinnaird T, E Stabile, MS Burnett and SE Epstein. (2004). Bone marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 95:354-363.
12. Kilroy GE, SJ Foster, X Wu, J Ruiz, S Sherwood, A Heifetz, JW Ludlow, DM Stricker, S Potiny, et al. (2007). Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 212:702-709.
13. Chen L, EE Tredget, PY Wu and Y Wu. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3:e1886.
14. Schinkothe T, W Bloch and A Schmidt. (2008). In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 17:199-206.
15. Krampera M. (2011). Mesenchymal stromal cell 'licensing': a multistep process. Leukemia 25:1408-1414.
16. English K, A French and KJ Wood. (2010). Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 7:431-442.
17. Uccelli A, L Moretta and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
18. Liu Y, R Mu, S Wang, L Long, X Liu, R Li, J Sun, J Guo, X Zhang, et al. (2010). Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 12:R210.
19. Lee HJ, JK Lee, H Lee, JW Shin, JE Carter, T Sakamoto, HK Jin and JS Bae. (2010). The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease. Neurosci Lett 481:30-35.
20. Zhou B, J Yuan, Y Zhou, M Ghawji, Jr., YP Deng, AJ Lee, U Nair, AH Kang, DD Brand and TJ Yoo. (2011). Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis. Clin Immunol 141:328-337.
21. Bai L, DP Lennon, V Eaton, K Maier, AI Caplan, SD Miller and RH Miller. (2009). Human bone marrow-derived mes-enchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57:1192-1203.
22. Shin L and DA Peterson. (2013). Human mesenchymal stem cell grafts enhance normal and impaired wound healing by recruiting existing endogenous tissue stem/progenitor cells. Stem Cells Transl Med 2:33-42.
23. Galipeau J. (2013). The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mes-enchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cy-totherapy 15:2-8.
24. Tongers J, DW Losordo and U Landmesser. (2011). Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 32:1197-1206.
25. Menard C, L Pacelli, G Bassi, J Dulong, F Bifari, I Bezier, J Zanoncello, M Ricciardi, M Latour, et al. (2013). Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their im-munomodulatory properties: standardization of immune quality controls. Stem Cells Dev 22:1789-1801.
26. Kerpedjieva SS, DS Kim, DJ Barbeau and K Tamama. (2012). EGFR ligands drive multipotential stromal cells to produce multiple growth factors and cytokines via early growth re-sponse-1. Stem Cells Dev 21:2541-2551.
27. Tamama K and DJ Barbeau. (2012). Early growth response genes signaling supports strong paracrine capability of mesenchymal stem cells. Stem Cells Int 2012:428403.
28. Silverman ES and T Collins. (1999). Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 154:665-670.
29. Thiel G and G Cibelli. (2002). Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193:287-292.
30. Le N, R Nagarajan, JY Wang, T Araki, RE Schmidt and J Milbrandt. (2005). Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Natl Acad Sci USA 102:2596-2601.
31. Street VA, CL Bennett, JD Goldy, AJ Shirk, KA Kleopa, BL Tempel, HP Lipe, SS Scherer, TD Bird and PF Chance. (2003). Mutation of a putative protein degradation gene LI-TAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 60:22-26.
32. Warner LE, P Mancias, IJ Butler, CM McDonald, L Keppen, KG Koob and JR Lupski. (1998). Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 18:382-384.
33. Safford M, S Collins, MA Lutz, A Allen, CT Huang, J Kowalski, A Blackford, MR Horton, C Drake, RH Schwartz and JD Powell. (2005). Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 6:472-480.
34. Okamoto T, T Aoyama, T Nakayama, T Nakamata, T Hos-aka, K Nishijo, T Nakamura, T Kiyono and J Toguchida. (2002). Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. Biochem Biophys Res Commun 295:354-361.
35. Tamama K, H Kawasaki, SS Kerpedjieva, J Guan, RK Ganju and CK Sen. (2011). Differential roles of hypoxia inducible factor subunits in multipotential stromal cells under hypoxic condition. J Cell Biochem 112:804-817.
36. ENCODE Project Consortium. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature 489:57-74.
37. ENCODE Project Consortium. (2011). A User's Guide to the Encyclopedia of DNA Elements (ENCODE). PLoS Biol 9:e1001046.
38. Nelson JD, O Denisenko and K Bomsztyk. (2006). Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1:179-185.
39. Shi Y, J Su, AI Roberts, P Shou, AB Rabson and G Ren. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 33:136-143.
40. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
41. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
42. Pio R, Z Jia, VT Baron and D Mercola. (2013). Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer. PLoS One 8:e54096.
43. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al. (2008). Me-senchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
44. Le Blanc K, I Rasmusson, B Sundberg, C Gotherstrom, M Hassan, M Uzunel and O Ringden. (2004). Treatment of severe acute graft-versus-host disease with third party haploi-dentical mesenchymal stem cells. Lancet 363:1439-1441.
45. Sbano P, A Cuccia, B Mazzanti, S Urbani, B Giusti, I Lapini, L Rossi, R Abbate, G Marseglia, et al. (2008). Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 300:115-124.
46. Harris JE, KD Bishop, NE Phillips, JP Mordes, DL Greiner, AA Rossini and MP Czech. (2004). Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J Immunol 173:7331-7338.
47. Francois M, R Romieu-Mourez, M Li and J Galipeau. (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20:187-195.
48. Kumbrink J, KH Kirsch and JP Johnson. (2010). EGR1, EGR2, and EGR3 activate the expression of their cor-egulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin. J Cell Bio-chem 111:207-217.
49. Sherry ST, MH Ward, M Kholodov, J Baker, L Phan, EM Smigielski and K Sirotkin. (2001). dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308-311.
50. Szigeti K, W Wiszniewski, GM Saifi, DL Sherman, N Sule, AM Adesina, P Mancias, S Papasozomenos, G Miller, et al. (2007). Functional, histopathologic and natural history study of neuropathy associated with EGR2 mutations. Neuroge-netics 8:257-262.
51. Warner LE, J Svaren, J Milbrandt and JR Lupski. (1999). Functional consequences of mutations in the early growth response 2 gene (EGR2) correlate with severity of human myelinopathies. Hum Mol Genet 8:1245-1251.
52. Ziebarth JD, A Bhattacharya, A Chen and Y Cui. (2012). PolymiRTS Database 2.0: linking polymorphisms in micro-RNA target sites with human diseases and complex traits. Nucleic Acids Res 40:D216-D221.
53. Ren G, J Su, L Zhang, X Zhao, W Ling, A L'Huillie, J Zhang, Y Lu, AI Roberts, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immuno-suppression. Stem Cells 27:1954-1962.
54. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, RC Zhao and Y Shi. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemo-kines and nitric oxide. Cell Stem Cell 2:141-150.